Leukemia Research
Volume 23, Issue 8 , Pages 695-700 , August 1999

Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine

  • Pia Raanani

      Affiliations

    • Institute of Hematology, The Chaim Sheba Medical Center, 52621 Tel-Hasomer, Israel
    • ,
  • Ofer Shpilberg

      Affiliations

    • Institute of Hematology, The Chaim Sheba Medical Center, 52621 Tel-Hasomer, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972-3-5302564; fax: +972-3-5340167
    • ,
  • Shmuel Gillis

      Affiliations

    • Department of Hematology, Hadassah University Hospital, Jerusalem, Israel
    • ,
  • Abraham Avigdor

      Affiliations

    • Institute of Hematology, The Chaim Sheba Medical Center, 52621 Tel-Hasomer, Israel
    • ,
  • Izhar Hardan

      Affiliations

    • Institute of Hematology, The Chaim Sheba Medical Center, 52621 Tel-Hasomer, Israel
    • ,
  • Miriam Berkowicz

      Affiliations

    • Institute of Hematology, The Chaim Sheba Medical Center, 52621 Tel-Hasomer, Israel
    • ,
  • Orit Sofer

      Affiliations

    • Institute of Hematology, The Chaim Sheba Medical Center, 52621 Tel-Hasomer, Israel
    • ,
  • Izidore Lossos

      Affiliations

    • Department of Hematology, Hadassah University Hospital, Jerusalem, Israel
    • ,
  • Angela Chetrit

      Affiliations

    • Institute of Epidemiology, The Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    • ,
  • Dina Ben-Yehuda

      Affiliations

    • Department of Hematology, Hadassah University Hospital, Jerusalem, Israel
    • ,
  • Isaac Ben-Bassat

      Affiliations

    • Institute of Hematology, The Chaim Sheba Medical Center, 52621 Tel-Hasomer, Israel

Received 5 October 1998 ,Revised 8 February 1999 ,Accepted 19 February 1999.

References 

  1. Cline MJ, Golde DW, Billing RJ, Groopman JE, Zighelboim J, Gale RP. Acute leukemia: biology and treatment. Ann. Intern. Med. 1979;91:758
  2. Cassileth PA, Begg CB, Bennett JM, Bozdech M, Kahn SB, Weiler C, et al. A randomized study of the efficacy of consolidation therapy in acute nonlymphocytic leukemia. Blood. 1984;63:843
  3. Champlin R, Gale RP. Acute myelogenous leukemia: recent advances in therapy. Blood. 1987;69:1551
  4. Gale RP, Foon KA. Therapy of acute myelogenous leukemia. Semin. Hematol. 1987;24:40
  5. Champlin R, Gajewski J, Nimer S, Vollset S, Landaw E, Winston D, et al.  Postremission chemotherapy for adults with acute myelogenous leukemia: Improved survival with high dose cytarabine and daunorubicin consolidation treatment. J. Clin. Oncol. 1990;8:1199
  6. Buchner T, Hiddemann W. Treatment strategies in acute myeloid leukemia (AML). First-line chemotherapy. Blut. 1990;60:61
  7. Schiller G. Treatment of resistant acute myeloid leukemia. Blood Rev. 1991;5:220
  8. Welborn JL. Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults. Am. J. Hematol. 1994;45:341
  9. Hilbe W, Thaler J, Eisterer W, Ludescher C, Niederwieser D. Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16). Leuk. Res. 1994;18:655
  10. Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP. High dose cytosine arabinoside therapy for refractory leukemia. Blood. 1983;62:361
  11. Hines JD, Oken MM, Mazza JJ, Keller AM, Streeter RR, Glick JH. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. J. Clin. Oncol. 1984;2:545
  12. Herzig RH, Lazarus HM, Wolff SN, Phillips GL, Herzig GP. High dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission induction of acute nonlymphoblastic leukemia. J. Clin. Oncol. 1985;3:992
  13. Gore M, Powles R, Lakhani A, Milan S, Maitland J, Goss G, et al  Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide. Cancer Chemother. Pharmacol. 1989;23:373
  14. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat. Report. 1983;67:389
  15. Prentice HG, Robbins G, Ma DDF, Ho AD. Mitoxantrone in relapsed and refractory acute leukemia. Semin. Oncol. 1984;11:32
  16. Ehninger G, Ho AD, Meyer P, Mjaaland I, Ostendorf P, Seither E. Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Onkologie. 1985;8:146
  17. Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, et al.  Phase I clinical and pharmacokinetic evaluation of high dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J. Clin. Oncol. 1993;11:2002
  18. Arlin ZA, Feldman EJ, Finger LR, Ahmed T, Mittelman A, Cook P, et al.  Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia. Leukemia. 1991;5:712
  19. Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, et al.  Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J. Clin. Oncol. 1989;7:1071
  20. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207
  21. Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Planker M, et al.  High dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin. Oncol. 1987;14(Suppl 1):73
  22. Hiddemann W, Buchner T, Heil G, Schumacher K, Diedrich H, Maschmeyer G, et al.  Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM). Leukemia. 1990;4:637
  23. Feldman EJ, Seiter K, Damon L, Linker C, Rugo H, Reis C, et al.  A randomized trial of high vs. standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia. 1997;11:485
  24. Kern W, Schleyer E, Unterhalt M, Wormann B, Buchner T, Hiddemann W. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. Cancer. 1997;79:59
  25. Weiss M, Maslak P, Feldman E, Berman E, Bertino J, Gee T, et al.  Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J. Clin. Oncol. 1996;14:2480
  26. Arlin ZA, Ahmed T, Mittelman A, Feldman E, Mehta R, Weinstein P, et al.  A new regimen of amsacrine with high dose cytarabine is safe and effective therapy for acute leukemia. J. Clin. Oncol. 1987;5:371
  27. Lejeune C, Tubiana N, Gastaut JA, Maraninchi D, Richard B, Launay MC, et al.  High dose cytosine arabinoside and mitoxantrone in previously treated acute leukemia patients. Eur. J. Haematol. 1990;44:240
  28. Keskin A, Tombuloglu M, Atamer MA, Buyukkececi F. Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia. Acta Haematol. 1994;92:14
  29. Kantarjian HM, Walters RL, Keating MJ, Estey EH, O’Brien S, Schachner J, et al.  Mitoxantrone and high dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukaemia. Cancer. 1990;65:5
  30. Amadori S, Arcese W, Isacchi G, Meloni G, Petti MC, Monarca B, et al.  Mitoxantrone, etoposide and intermediate dose cytarabine. An effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J. Clin. Oncol. 1991;9:1210
  31. Sierra J, Granena A, Bosch F, Carreras E, Marti JM, Urbano-Ispizua A, et al.  Mitoxantrone and intermediate dose cytosine arabinoside for poor risk acute leukemias: response to treatment and factors influencing outcome. Hematol. Oncol. 1992;10:301
  32. Larson RA, Day RS, Azarnia N, Bennett JM, Browman G, Goldberg J, et al.  The selective use of AMSA following high dose cytarabine in patients with acute myeloid leukemia in relapse: a leukemia intergroup study. Br. J. Haematol. 1992;82:337
  33. Damon LE, Rugo HS, Ries CA, Linker CA. Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia. Leukemia. 1994;8:535
  34. Damon LE, Rugo HS, Ries CA, Linker CA. Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia. Bone Marrow Transpl. 1996;17:93
  35. Davis CL, Rohatiner AZS, Lim J, Whelan JS, Oza AM, Amess J, et al.  The management of recurrent acute myelogenous leukaemia at a single center over a fifteen year period. Br. J. Haematol. 1993;83:404

PII: S0145-2126(99)00078-8

Leukemia Research
Volume 23, Issue 8 , Pages 695-700 , August 1999

Article Tools

* Image Usage & Resolution